Gross margins of 86.8% can't hide inventory days exploding from 102 to 377 in one quarter.
A pharmaceutical company with fortress-like margins and pricing power trades inventory efficiency for institutional confidence while charging premium prices for stable, predictable cash flows.
Does this business have an enduring competitive advantage that protects returns on capital?
This framework sees a wide moat built on regulatory barriers, switching costs in life-critical medications, and pricing power that produces gross margins most businesses only dream of. The HIV franchise dominance creates both strength and concentration risk.
How much real cash does an owner get to keep after maintaining the business?
Applying this lens reveals troubling divergence — strong reported margins mask deteriorating cash conversion. The framework values cash generation over accounting profits, and the working capital explosion suggests owner earnings quality is declining despite headline strength.
Are earnings predictable and consistent enough to rely on for decades?
This framework appreciates the high beat rate and margin recovery but notes concerning volatility. The extreme operating leverage means small revenue changes create large earnings swings — not the predictability this framework seeks.
If you bought this entire business today, would what it earns justify what you paid?
Through this lens, the math requires faith. The framework sees a business earning less than treasuries while the market prices in growth rates that would make young tech companies envious. For a permanent owner seeking certainty, these numbers don't compute.
Can this business deploy incremental capital at high rates of return?
This framework sees mixed reinvestment signals. While ROIC exceeds WACC, the concentration in HIV limits growth runways and management's buyback timing destroyed shareholder value — suggesting capital allocation skills don't match operational excellence.
This framework sees a business with undeniable competitive advantages — 86.8% gross margins and dominant market positions create the moat Buffett values. Yet the owner's math struggles with earnings yielding less than treasuries while working capital efficiency collapses. The divergence between institutional accumulation and insider selling suggests smart money disagrees about the future. Is this a great business at a poor price, or are the working capital problems signaling deeper operational decay?
This analysis applies Warren Buffett's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Warren Buffett. Educational purposes only. Not financial advice.